Our Subsidiary Model

• Portfolio diversification, for mitigated risk and maximized opportunity
• Shared infrastructure for enhanced operational efficiency
• More effective R&D, with better focus on advancing programs
• Financial flexibility, with ability to raise funds at parent or subsidiary level
• Attractiveness to potential employees and stakeholders, with research opportunities across multiple modalities

Fastback Bio’s vision is to apply its novel technology platform to difficult-to-treat oncology indications. Focused on applying its novel co-stimulatory technology to T-cell therapeutics for the most difficult-to-treat tumors, from hematological malignancies to renal cell carcinoma, ovarian cancer, and triple-negative breast cancer. The technology was licensed from the University of North Carolina, Chapel Hill, where they continue to partner with the FastBack Bio team to drive this foundational innovation into reality for patients who so desperately need help.